Head-To-Head Contrast: Profusa (NASDAQ:PFSA) and OraSure Technologies (NASDAQ:OSUR)
by Kim Johansen · The Markets DailyProfusa (NASDAQ:PFSA – Get Free Report) and OraSure Technologies (NASDAQ:OSUR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Profitability
This table compares Profusa and OraSure Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -1,731.09% |
| OraSure Technologies | -43.70% | -19.09% | -16.26% |
Valuation and Earnings
This table compares Profusa and OraSure Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profusa | $100,000.00 | 13.30 | -$35.82 million | ($5,619.96) | -0.00 |
| OraSure Technologies | $115.02 million | 2.36 | -$68.73 million | ($0.69) | -5.70 |
Profusa has higher earnings, but lower revenue than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
9.8% of Profusa shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 15.0% of Profusa shares are owned by company insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Profusa has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Profusa and OraSure Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| OraSure Technologies | 1 | 1 | 0 | 0 | 1.50 |
OraSure Technologies has a consensus price target of $3.00, indicating a potential downside of 23.66%. Given OraSure Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe OraSure Technologies is more favorable than Profusa.
Summary
OraSure Technologies beats Profusa on 7 of the 13 factors compared between the two stocks.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
About OraSure Technologies
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.